# Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

> **NCT02560051** · PHASE2 · TERMINATED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 19 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Ketoconazole
- **DRUG:** Docetaxel
- **DRUG:** Estramustine
- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT02560051
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2017-09-12
- **Final completion:** 2017-09-14
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Slow accrual; resource re-allocation
- **Last updated:** 2018-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02560051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02560051, "Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02560051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*